Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 9/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.49 |
| ▸ | FLT1 | P17948 | 6/20 | 0.48 |
| ▸ | FLT4 | P35916 | 6/20 | 0.48 |
| ▸ | KDR | P35968 | 6/20 | 0.48 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7459021 | 0.85 | FLT1 (0.50) | FLT1FLT4KDR | |
| SCHEMBL7461533 | 0.83 | GRIK1 (0.51) | GRIK1FLT1FLT4KDRNLRP3 | |
| SCHEMBL3788016 | 0.82 | FLT1 (0.52) | FLT1FLT4KDR | |
| SCHEMBL7469556 | 0.81 | TP53 (0.46) | FBP1GRIK1FLT1FLT4KDR | |
| SCHEMBL3782284 | 0.81 | FLT1 (0.48) | GRIK1FLT1FLT4KDR | |
| SCHEMBL7461264 | 0.81 | FLT1 (0.59) | FLT1FLT4KDR | |
| SCHEMBL3783035 | 0.80 | FLT1 (0.43) | GRIK1FLT1FLT4KDR | |
| SCHEMBL7470188 | 0.80 | GRIK1 (0.45) | GRIK1 | |
| SCHEMBL3786900 | 0.79 | ALDH1A1 (0.40) | FBP1GRIK1FLT1FLT4KDR | |
| SCHEMBL3786902 | 0.79 | ALDH1A1 (0.40) | FBP1GRIK1FLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1142586-B1 | USE OF CHYMASE INHIBITORS AGAINST VASCULAR LIPID DEPOSITION | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-6921766-B1 | Blood vessel lipid deposition-preventive agent comprising chymase-inhibitor | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-07-26 | — | — | US | disclosed |
| US-20050148608-A1 | Quinazoline derivatives and pharmaceutical applications thereof | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| US-6677344-B2 | Chymase inhibitor for the treatment of eosinophilia | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20020187989-A1 | Preventive or therapeutic drugs for various eosinophilia-related diseases containg chymase inhibitors as the active ingredient | ASUBIO PHARMA CO., LTD. (JP) | 2002-12-12 | — | — | US | disclosed |
| EP-1142586-A1 | INHIBITORS AGAINST VASCULAR LIPID DEPOSITION CONTAINING CHYMASE-INHIBITING SUBSTANCES | SUNTORY LIMITED (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187989-A1 | Preventive or therapeutic drugs for various eosinophilia-related diseases containg chymase inhibitors as the active ingredient | CMA1, SERPINB1, EPX | FBP1 1731/4885GRIK1 3400/4885FLT1 3866/4885 |
| US-20050148608-A1 | Quinazoline derivatives and pharmaceutical applications thereof | CMA1, ACE, ACE2 | FBP1 2131/4885GRIK1 1486/4885FLT1 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.